A study shows that Romanian patients wait, on average, 460 days for access to innovative medicines, seriously affecting critical areas such as oncology.

An analysis carried out by Novartis Romania highlights the long delays in Romanian patients' access to innovative medicines, with an average of 460 days from the approval of compensation by the ANMDM. Oncology is the most affected, with 40% of the indications analyzed. Although the assessment process has improved, the compensation steps remain lengthy. The study emphasizes the need for reforms in the reimbursement system to ensure rapid and equitable access to treatment.